BACKGROUND: Genetic susceptibility in lung cancer risk has long been recognized but remains ill defined, as does the role of tobacco smoke exposure and chronic obstructive pulmonary disease (COPD). METHODS: Using a dual case-control design, we tested whether alpha(1)-antitrypsin deficiency (alpha(1)ATD) carriers are predisposed to a higher risk of lung cancer, adjusting for the effects of tobacco smoke exposure and COPD. A total of 1856 patients with incident lung cancer were included in the study; 1585 community residents served as controls. A second control group was composed of 902 full siblings of the patients. We first modeled 1585 case-control pairs without the alpha(1)ATD variable using multiple logistic regression analysis and then modeled the alpha(1)ATD allele type in the presence of other known risk factors of lung cancer. RESULTS: We found a significantly increased lung cancer risk among alpha(1)ATD carriers from 2 parallel case-control comparisons: when patients were compared with unrelated controls, alpha(1)ATD carriers had a 70% higher risk of developing lung cancer than noncarriers (odds ratio, 1.7; 95% confidence interval, 1.2-2.4). In a further comparison of patients with their cancer-free siblings, we found a 2-fold increased lung cancer risk in alpha(1)ATD carriers (95% confidence interval, 1.4-2.7). Stratified analysis by tumor histologic subtypes showed a significant increase for adenocarcinoma and squamous cell carcinoma among alpha(1)ATD carriers. CONCLUSION: Our results suggest that alpha(1)ATD carriers are at a 70% to 100% increased risk of lung cancer and may account for 11% to 12% of the patients with lung cancer in our study.
BACKGROUND: Genetic susceptibility in lung cancer risk has long been recognized but remains ill defined, as does the role of tobacco smoke exposure and chronic obstructive pulmonary disease (COPD). METHODS: Using a dual case-control design, we tested whether alpha(1)-antitrypsin deficiency (alpha(1)ATD) carriers are predisposed to a higher risk of lung cancer, adjusting for the effects of tobacco smoke exposure and COPD. A total of 1856 patients with incident lung cancer were included in the study; 1585 community residents served as controls. A second control group was composed of 902 full siblings of the patients. We first modeled 1585 case-control pairs without the alpha(1)ATD variable using multiple logistic regression analysis and then modeled the alpha(1)ATD allele type in the presence of other known risk factors of lung cancer. RESULTS: We found a significantly increased lung cancer risk among alpha(1)ATD carriers from 2 parallel case-control comparisons: when patients were compared with unrelated controls, alpha(1)ATD carriers had a 70% higher risk of developing lung cancer than noncarriers (odds ratio, 1.7; 95% confidence interval, 1.2-2.4). In a further comparison of patients with their cancer-free siblings, we found a 2-fold increased lung cancer risk in alpha(1)ATD carriers (95% confidence interval, 1.4-2.7). Stratified analysis by tumor histologic subtypes showed a significant increase for adenocarcinoma and squamous cell carcinoma among alpha(1)ATD carriers. CONCLUSION: Our results suggest that alpha(1)ATD carriers are at a 70% to 100% increased risk of lung cancer and may account for 11% to 12% of the patients with lung cancer in our study.
Authors: Ping Yang; Mark S Allen; Marie C Aubry; Jason A Wampfler; Randolph S Marks; Eric S Edell; Stephen Thibodeau; Alex A Adjei; James Jett; Claude Deschamps Journal: Chest Date: 2005-07 Impact factor: 9.410
Authors: Ken Taniguchi; Ping Yang; James Jett; Eric Bass; Rebecca Meyer; Yunjie Wang; Claude Deschamps; Wanguo Liu Journal: Clin Cancer Res Date: 2002-04 Impact factor: 12.531
Authors: M de Andrade; J O Ebbert; J A Wampfler; D L Miller; R S Marks; G A Croghan; A Jatoi; E E Finke; T A Sellers; P Yang Journal: Lung Cancer Date: 2004-02 Impact factor: 5.705
Authors: Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: Darcy D Marciniuk; P Hernandez; M Balter; J Bourbeau; K R Chapman; G T Ford; J L Lauzon; F Maltais; D E O'Donnell; D Goodridge; C Strange; A J Cave; K Curren; S Muthuri Journal: Can Respir J Date: 2012 Mar-Apr Impact factor: 2.409
Authors: James D Bortner; Arunangshu Das; Todd M Umstead; Williard M Freeman; Richard Somiari; Cesar Aliaga; David S Phelps; Karam El-Bayoumy Journal: J Proteome Res Date: 2009-08 Impact factor: 4.466
Authors: Tyler McGrady; David M Mannino; Elisha Malanga; Byron M Thomashow; John Walsh; Robert A Sandhaus; James K Stoller Journal: Chronic Obstr Pulm Dis Date: 2015-04-15
Authors: Susan E Olivo-Marston; Ping Yang; Leah E Mechanic; Elise D Bowman; Sharon R Pine; Christopher A Loffredo; Anthony J Alberg; Neil Caporaso; Peter G Shields; Stephen Chanock; Yanhong Wu; Ruoxiang Jiang; Julie Cunningham; Jin Jen; Curtis C Harris Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254
Authors: Xifeng Wu; Liang Wang; Yuanqing Ye; Jeremiah A Aakre; Xia Pu; Gee-Chen Chang; Pan-Chyr Yang; Jack A Roth; Randolph S Marks; Scott M Lippman; Joe Y Chang; Charles Lu; Claude Deschamps; Wu-Chou Su; Wen-Chang Wang; Ming-Shyan Huang; David W Chang; Yan Li; V Shane Pankratz; John D Minna; Waun Ki Hong; Michelle A T Hildebrandt; Chao Agnes Hsiung; Ping Yang Journal: Cancer Res Date: 2013-05-23 Impact factor: 12.701
Authors: Jill Koshiol; Melissa Rotunno; Dario Consonni; Angela Cecilia Pesatori; Sara De Matteis; Alisa M Goldstein; Anil K Chaturvedi; Sholom Wacholder; Maria Teresa Landi; Jay H Lubin; Neil E Caporaso Journal: PLoS One Date: 2009-10-08 Impact factor: 3.240